Clinical Trial Detail

NCT ID NCT02897765
Title A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Neon Therapeutics, Inc.
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

melanoma

lung non-small cell carcinoma

urethra transitional cell carcinoma

Therapies

Nivolumab

NEO-PV-01 + Poly ICLC

Age Groups: adult senior

No variant requirements are available.